Robert A. Weeks
Pfizer
5 Papers
80 Citations
Robert A. Weeks is an academic researcher from Pfizer. The author has contributed to research in topics: Prazosin & Yohimbine. The author has an hindex of 4, co-authored 5 publications.
Chat about Author
Papers
α2- and α2-vasular adrenoceptors in the dog
TL;DR: The results suggest that pressor effects in dogs are mediated by both α 1 - and α 2 -vascular (i.e. postsynaptic) adrenoceptors.
63
Prazosin and presynaptic alpha-receptors in the cardioaccelerator nerve of the dog
TL;DR: The results indicate that prazosin, like phentolamine and yohimbine, blocks presynaptic α-adrenergic receptors on the cardiac accelerator nerve of the dog but, unlike yohimbe, prazoin does not block these receptors on noradren allergic nerves of rabbit pulmonary artery.
49
The hypotensive effect of trimazosin is not caused solely by alpha 1-adrenoceptor blockade.
TL;DR: In addition to alpha 1-adrenoceptor blockade, another mechanism contributes to the hypotensive effect of trimazosin, and it is speculated that elevation of cyclic GMP levels in vascular smooth muscle may be related to this additional mechanism.
9
Effects of trimazosin and prazosin on blood pressure and on pressor responses to phenylephrine in rats.
TL;DR: Preliminary results indicate that trimazosin was less potent but more efficacious in lowering blood pressure than was prazosin and caused less blockade of the alpha-1-adrenoceptors even when its hypotensive effect exceeded that of prazoin.
6
Blockade of central alpha 2-adrenoceptors enhances the carotid occlusion response in dogs.
TL;DR: It is concluded that enhancement of the BCO response by yohimbine and rauwolscine is caused by blockade of central α2-adrenoceptors.
3